Australian Nanotech Starpharma To Develop A Second Generation Microbicide For The Prevention Of Infection By HIV

Melbourne-based nanotechnology company Starpharma will lead a consortium to develop a second generation microbicide for the prevention of infection by HIV and other sexually transmitted diseases (STDs). This consortium is being funded by a US$5.4 million (A$7.5 million) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). The consortium consists of Starpharma and ReProtect, Inc., together with research groups from the Johns Hopkins University, the University of Texas Medical Branch, the University of Kentucky, the University of Washington and the Burnet Institute in Melbourne.